Human factors validation study of a disposable autoinjector (Bmab 1200 autoinjector) for subcutaneous delivery of Ustekinumab
= 7), none causing device damage or failed delivery. The knowledge task success rate was 99.6% (2,511/2,520 measures). Nine use errors (study artifacts or inattention to instructions) occurred only among caregivers. All participants expressed confidence in safe dosing and found the device user-friendly. The Bmab 1200 autoinjector demonstrated high usability and safety across diverse users for ustekinumab biosimilar delivery in chronic autoimmune conditions.
Authors
- Rohini Kamaraj (ORCID: https://orcid.org/0009-0001-3343-3262)
- Sam Moses K (ORCID: https://orcid.org/0009-0008-0981-439X)
- Suryaprakash Konda Ramachary Subramanian (ORCID: https://orcid.org/0009-0007-3782-9567)
Institutions
- Biocon (Switzerland) (CH)
Publication Details
- Journal
- Drug Delivery
- Published
- 2026-05-29
- DOI
- https://doi.org/10.1080/10717544.2026.2680354
- Primary Topic
- vaccines and immunoinformatics approaches
- Type
- article
- Field-Weighted Citation Impact
- 0.00